Abstract:

This paper aims at valuating Pfizer, Inc., one of the world’s most cited company during the last few years, due to its fundamental role in keeping the COVID-19 Pandemic under control through the vaccine developed in collaboration with BioNTech. How did the vaccine change the financial statements of the company? Two valuation methods – Discounted Cash Flow Method and Multiple Valuation Method – are used in order to determine if Pfizer is undervalued or overvalued and to conclude if the value-creation objective that it has for its shareholders is achieved.